Class summary at a glance.

Every drug in the Nitroimidazole Antimicrobial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 9tracked in Part D
CY24 Part D spend: $88.0Mcombined across class
Total Rx claims: 3.4M2.6M unique beneficiaries
Generic mfrs (active): 29across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Metronidazole

Brand: Flagyl · 3.4M Part D claims (CY24) · 2.6M beneficiaries · First FDA approval: 1981-12-24

24 generic mfrs 33 plans require PA Active FDA shortage

Low NADAC$0.071

→

Avg plan cost$0.866

Part D spend $87.3M 12× spread, current vs floor

Class share

99%

of class CY24 spend

View profile →

Tinidazole

Brand: Tindamax · 14K Part D claims (CY24) · 11K beneficiaries · First FDA approval: 2004-05-17

3 generic mfrs 0 plans require PA

Low NADAC$1.37

→

Avg plan cost$1.88

Part D spend $621205 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Secnidazole

Brand: Solosec · 286 Part D claims (CY24) · 233 beneficiaries · First FDA approval: 2018-05-31

Brand-only (no generics) 1 plans require PA

Low NADAC$283.15

→

Avg plan cost$283.15

Part D spend $88144 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Bismuth Subcitrate Potassium, Metronidazole and Tetracycline

— Part D claims (CY24) · First FDA approval: 2023-03-07

Brand-only (no generics) 0 plans require PA

Low NADAC$3.15

→

Avg plan cost$3.15

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Bismuth Subcitrate Potassium, Metronidazole, Tetracycline

— Part D claims (CY24) · First FDA approval: 2023-07-04

2 generic mfrs

Low NADAC$3.15

→

Avg plan cost$3.15

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Fexinidazole

— Part D claims (CY24) · First FDA approval: 2021-07-16

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Metronidazole Oral

Brand: LIKMEZ · — Part D claims (CY24) · First FDA approval: 2023-10-13

Brand-only (no generics)

Low NADAC$2.60

→

Avg plan cost$2.61

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Metronidazole Topical

Brand: METRONIDAZOLE · — Part D claims (CY24) · First FDA approval: 2025-01-28

Brand-only (no generics)

Low NADAC$0.333

→

Avg plan cost$0.333

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Metronidazole Vaginal Gel,

Brand: Metronidazole Vaginal Gel · — Part D claims (CY24) · First FDA approval: 2024-03-19

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.